Article

Phakic IOL useful for high myopia, hyperopia, astigmatism

An iris-fixed phakic IOL (Verisyse/Artisan, Advanced Medical Optics) is effective in correcting high myopia, hyperopia, and astigmatism, according to 5-year follow-up data from a prospective study conducted in France.

Keypoints:

Nantes, France-Five-year follow-up data on eyes in which an iris-fixed phakic IOL (Verisyse/Artisan, Advanced Medical Optics) had been implanted, show that the lens is effective in correcting high myopia, hyperopia, and astigmatism. The most frequent long-term complications found in the study were endothelial cell density loss and IOL decentration, said Joanna Brejtfus, MD, Clinique Sourdille, Nantes, France.

The 5-year outcomes also indicate that lens dislocation can occur at any time after surgery and that cell loss in eyes with iris-claw IOLs is greater than it is in normal eyes without surgery, said Dr. Brejtfus.

"Careful follow-up, searching for subclinical subluxation and endothelial cell loss, is necessary," she said. "Endothelial cell counts should be performed every year as long as the lens remains in the eye."

Early postoperative complications included temporary elevation of IOP, undercorrection requiring IOL exchange or a laser procedure, inflammatory reaction in the anterior chamber, small pupil ovalization, and pupil block.

Significant late complications included endothelial cell loss and subluxation of the implant.

"We observed important endothelial loss in 40% of the eyes during follow-up," Dr. Brejtfus said. "The most significant finding of up to 70% loss of endothelial cell density occurred in seven eyes."

Although several cases of retinal detachment occurred among the patients in this study, Dr. Brejtfus said she did not believe that any correlation existed between the detachments and refractive surgery.

In the study population, nine eyes had both severe endothelial cell loss and implant subluxation treated by IOL fixation.

Dr. Brejtfus also noted that significant endothelial cell loss was observed beginning in the third year after surgery. Because no patients experienced severe endothelial cell density loss before then, it appears that the length of time that the phakic IOL remains in the eye could be a risk factor.

Analysis of the outcomes also showed that acute implant decentration was associated with loss of vision, ocular pain, and photophobia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.